Sickle Cell Anemia Testing & Screening Market - Global Forecast 2025-2032

The sickle cell anemia testing and screening market is evolving, shaped by diagnostic innovations, regulatory adjustments, and global health initiatives. Senior decision-makers must understand these shifts to navigate changing demands and optimize their organization’s strategy in this essential healthcare segment.

Market Snapshot: Sickle Cell Anemia Testing & Screening Market

The Sickle Cell Anemia Testing & Screening Market advanced from USD 1.07 billion in 2024 to USD 1.21 billion in 2025, reflecting a strong compound annual growth rate of 13.90%. The market is projected to reach USD 3.03 billion by 2032. This robust expansion is attributed to a combination of rising government and non-profit programs focused on early detection, as well as continuous technological advancements in diagnostic platforms. Enhanced laboratory tool accuracy, improved workflow efficiencies, and greater scalability strengthen the core value proposition for healthcare organizations seeking reliable and efficient testing capabilities.

Scope & Segmentation of the Sickle Cell Anemia Testing & Screening Market

This report delivers a comprehensive analysis of the sickle cell diagnostics landscape, assessing technology adoption, product categories, and end-user priorities in all key geographies and with major industry stakeholders.

• Test Types: Examination of high-performance liquid chromatography (HPLC), various immunoassays including enzyme-linked immunosorbent and lateral flow formats, and molecular testing through next-generation sequencing as well as polymerase chain reaction.
• Product Categories: Extensive coverage of consumables such as assay kits and reagents, laboratory instruments including HPLC systems, immunoassay analyzers, molecular diagnostic platforms, and services for technical support, maintenance, hands-on training, and consultancy.
• End Users: Analysis of diagnostic laboratories in hospital and independent settings, public and private clinics, along with academic and governmental research institutes.
• Sample Types: Review of capillary and venous blood sampling as well as saliva, collected via kits or direct capture methods, enabling procedural flexibility across different clinical workflows.
• Distribution Channels: Insight into company-owned direct sales, third-party distributors, and online retail partnerships, supporting broad market access in both traditional and emerging healthcare environments.
• Regional Markets: Focus on the Americas, Europe, Middle East & Africa, and Asia-Pacific, with in-depth coverage of vital markets including the United States, Canada, Brazil, United Kingdom, Germany, France, China, India, Japan, and South Africa.
• Key Companies Profiled: Profiles include F. Hoffmann-La Roche Ltd, Abbott Laboratories, Thermo Fisher Scientific Inc., Bio-Rad Laboratories, Inc., Becton, Dickinson and Company, Siemens Healthineers AG, DiaSorin S.p.A., PerkinElmer, Inc., Ortho Clinical Diagnostics, Inc., and QIAGEN N.V.

Sickle Cell Anemia Testing & Screening Market: Key Takeaways for Senior Decision-Makers

• Advances in chromatography, immunoassays, and molecular diagnostics are enhancing reliability for both centralized laboratories and point-of-care testing, helping providers serve a wider range of patient populations.
• Digital health integration now supports real-time analytics and remote reporting, which expands access, especially in underserved regions and aligns with equity-driven healthcare goals.
• Collaboration between established market leaders, innovative startups, and academic institutions is fast-tracking technology validation, speeding up routes to commercial adoption and clinical implementation.
• Expanded service offerings, such as comprehensive technical support and digital training, are fostering stronger customer loyalty and equipping users to maximize testing investments.
• Regional differences in regulatory frameworks and infrastructure readiness continue to shape the expansion of testing services, necessitating adaptable delivery models in response to diverse public health needs.

Tariff Impact on Market Dynamics

Anticipated U.S. tariff changes in 2025 are impacting the pricing and availability of laboratory platforms and consumables necessary for sickle cell diagnostics. Leading manufacturers are addressing this challenge by shifting toward regional sourcing strategies and relocating aspects of production to reduce cost volatility. Additionally, organizations are deploying bundled service strategies and advocating for policy changes while diversifying supply chains to enhance operational resilience and ensure market continuity under changing trade policies.

Research Methodology & Data Sources

This report’s analysis is based on a hybrid methodology, triangulating regulatory filings, scientific literature, and first-hand interviews with laboratory leaders, clinicians, vendors, and healthcare payers. The integrated use of quantitative and qualitative sources ensures a reliable, holistic perspective on market trends.

Why This Report Matters

• Enables senior executives to benchmark strategies, optimize testing portfolios, and adapt distribution approaches according to shifting regional and global trends.
• Equips risk management teams to respond proactively to regulatory updates, tariff impacts, and evolving dynamics influencing the sickle cell anemia testing and screening ecosystem.

Conclusion

Senior decision-makers gain actionable market intelligence and focused insight from this report, supporting strategic planning and investment in the expanding sickle cell anemia testing sector.

Additional Product Information:

• Purchase of this report includes 1 year online access with quarterly updates.
• This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.